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Anionic bubble lipopolyplexes have been developed as anionic ultrasound (US)-responsive gene delivery carriers 
with biocompatible compounds for efficient and safe transfection in mice. The particles of the anionic bubble 
lipopolyplexes were approximately 450–600 nm with an anionic surface charge. In the absence of US exposure, the 
bubble lipopolyplexes showed extremely low gene expression in the human vascular endothelial cell line EAhy926. 
The anionic bubble lipopolyplexes, however, delivered pDNA into cells without endocytosis and showed markedly 
high gene expression following US exposure. The anionic bubble lipopolyplexes showed little cytotoxicity in 
EAhy926 cells and little aggregation with erythrocytes. Following intravenous administration into mice, the anionic 
bubble lipopolyplexes showed high levels of gene expression in the liver, kidney, and spleen only after US 
exposure to the abdominal area. The level of gene expression in liver non-parenchymal cells was significantly 
higher than that in parenchymal cells. In addition, the anionic bubble lipopolyplexes did not show any severe 
hepatic toxicity and did not enhance the production of proinflammatory cytokines. Overall, we have succeeded in 
preparing anionic bubble lipopolyplexes for efficient and safe transfection with US exposure in mice. 
 




It is largely expected that gene therapy will provide a range of novel approaches for the treatment of 
genetic disorders and intractable diseases such as cancer [1-3]. Advances in this area, however, have been limited 
by the fact that naked plasmid DNA (pDNA) is readily degraded in vivo and barely taken up by cells. To date, a 
variety of different gene delivery methods have been developed to take full advantage of gene therapy, and these 
gene delivery methods can be categorized as either viral or non-viral methods [4, 5]. Non-viral gene delivery 
methods have several advantages over the viral methods, such as providing the flexibility to design a vehicle with 
well-defined structural and chemical properties capable of mass production [6, 7]. Non-viral gene delivery methods 
can also be split into two sub-categories, with one involving the use of gene delivery carriers such as cationic 
polymers and liposomes, and the other involving the use of naked pDNA molecules according to the 
electroporation, hydrodynamic, pressure, and suction methods [8-12]. Most of the gene delivery carriers deliver the 
pDNA into cells through endocytosis. Unfortunately, however, intracellular delivery from endosomes to the cytosol 
provides a major obstacle to gene expression [13]. 
 Sonoporation, which is a combination of ultrasound (US) exposure and microbubbles containing US 
imaging gas, has recently been reported to deliver pDNA directly into the cytosol without endocytosis and show 
high levels of gene expression [14, 15]. US exposure disrupts the microbubbles and generates cavitation energy 
[16], which can create transient pores in the cellular membrane that allow pDNA to be delivered into the cytosol 
[15, 17]. In addition, some novel approaches have been developed to allow for the incorporation of non-viral gene 
delivery carriers with microbubbles using covalent binding, as well as avidin-biotin and electrostatic interactions 
[18-24]. 
The microbubbles are generally several micrometers in size, which generally prevents these materials 
from reaching the peripheral tissues following intravenous administration. Maruyama et al. recently succeeded in 
developing a novel formulation capable of producing bubble liposome particles of approximately 500 nm in size 
[25, 26]. In our previous study, we reported the development of mannosylated bubble lipoplexes for the targeted 
delivery of pDNA and siRNA into macrophages [27-29]. With regard to the surface charge of the bubble lipoplexes, 
those possessing an anionic or neutral surface charge were suitable for clinical application because cationic charged 
lipoplexes have been reported to interact with biogenic substances such as serum albumin and erythrocytes [30]. 
Given that neutral bubble lipoplexes can readily aggregate through the neutralization of their electric charge, it was 
envisaged that the anionic bubble lipopolyplexes could be prepared without aggregation even under high 
concentration conditions. There have, however, been very few reports concerning the development or application of 
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US responsive gene delivery carriers with an anionic surface charge. With all of this in mind, we prepared bubble 
lipopolyplexes as novel anionic US responsive gene delivery carriers from a ternary pDNA complex, cationic 
polymers, and anionic bubble liposomes with biocompatible compounds for efficient and safe transfection. 
In this study, we have investigated the physicochemical properties, transfection efficiencies, and toxicity 
of the anionic bubble lipopolyplexes before and after US exposure. 
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2. Materials and methods 
2.1. Chemicals 
Protamine sulfate (PS), poly-L-lysine (PLL), poly-L-arginine (PLA), and polyethylenimine (PEI, 
branched form, average molecular weight 25,000) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Dendrigraft poly-L-lysine (DPLL) was purchased from Colcom (Montpellier, France). Distearoyl 
phosphatidylglycerol (DSPG), distearoyl phosphatidylic acid (DSPA), distearoyl phosphatidylserine (DSPS), 
distearoyl phosphatidylcholine (DSPC), and dioleoyl trimethylammoniumpropane (DOTAP) were obtained from 
Avanti Polar Lipids Inc. (Alabaster, AL, USA). Cholesterol (Chol) and methoxy-polyethyleneglycol 
2000-distearoylphosphatidylethanolamine (PEG-DSPE) were purchased by Nacalai Tesque (Kyoto, Japan) and 
NOF Co. (Tokyo, Japan), respectively. All of the other chemicals used in the current study were purchased as the 
highest purity grades available. 
 
2.2. Construction of pDNA 
pCMV-Luc was used as described previously [31]. The pDNA was amplified using an EndoFree Plasmid 
Giga Kit (Qiagen GmbH, Hilden, Germany) and dissolved in sterile dH2O. Fluorescein-labeled pDNA was 
prepared using a Label IT Tracker Fluorescein Kit (Mirus Co., Madison, WI, USA). 
 
2.3. Preparation of the anionic bubble lipopolyplexes 
DSPG, DSPC, and PEG-DSPE were mixed in chloroform in a molar ratio of 7:2:1 for the construction of 
the anionic liposomes (AL). The resulting lipid mixture was then dried by evaporation before being desiccated in a 
vacuum to give a lipid film, which was subsequently suspended in sterile dH2O. Following a 30-min period of 
hydration at 65°C, the dispersion was sonicated for 10 min using a bath sonicator, and then sonicated in a tip 
sonicator for 3 min to produce liposomes, which were sterilized using a 0.45-μm filter (Nihon-Millipore, Tokyo, 
Japan). 
Various cationic polyplexes were prepared by gently mixing a pDNA solution with an appropriate amount 
of a cationic polymer solution such as PS, PLL, PLA, or DPLL, with the resulting mixture being incubated for 15 
min. The resulting cationic polyplexes were then mixed with the appropriate amount of the AL to allow for the 
construction of the anionic lipopolyplexes. Various anionic lipopolyplexes were also constructed at weight ratios of 
1.0:1.5:17.6 (pDNA:PLL, PLA, or DPLL:AL) or 1.0:1.25:2.5 (pDNA:PS:AL). The isotonicity properties of the 
solutions were then adjusted via the addition of 10× phosphate buffered saline (PBS). For the preparation of the 
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bubble lipopolyplexes (pDNA/PS, PLL, PLA, and DPLL/BL), US imaging gas captured within the anionic 
lipopolyplexes using a method described previously in the literature [32]. Briefly, the anionic lipopolyplexes were 
added to 5-mL sterilized vials, which were subsequently capped and pressurized with 7.5 mL of perfluoropropane 
gas (Takachiho Chemical Industries Co., Ltd., Tokyo, Japan). To enable the US imaging gas to become 
encapsulated within the anionic lipopolyplexes, the vial was sonicated in a bath-type sonicator (AS ONE Co., 
Osaka, Japan) for 5 min. For the optimization of the anionic lipids, three anionic liposomes containing DSPG, 
DSPA, or DSPS were prepared and pDNA/PS/AL and pDNA/PS/BL were developed for each of the anionic 
liposomes.  
 
2.4. Physicochemical properties of the anionic bubble lipopolyplexes 
The particle sizes and zeta-potentials of the bubble lipopolyplexes were measured using a Zetasizer Nano 
ZS (Malvern Instruments Ltd., Worcestershire, United Kingdom). 
Ten-microliter aliquots of different complex solutions containing 1 μg of pDNA were mixed with 2 µL of 
loading buffer (30% glycerol and 0.2% bromophenol blue) and loaded onto a 1% agarose gel. Electrophoresis 
(Mupid-2X; Cosmo Bio, Tokyo, Japan) experiments were carried out at 100 V in a running buffer solution (40 mM 
Tris/HCl, 40 mM acetic acid, and 1 mM EDTA). The pDNA was visualized with a GelRed Nucleic Acid Gel Stain 
(Wako, Osaka, Japan) using an ImageQuant LAS4000 System (GE Healthcare Life Sciences, Fairfield, CT, USA). 
Transmission electron microscope (TEM) images of the pDNA/PS, pDNA/PS/AL, and pDNA/PS/BL were 
recorded on a H-7650 system (Hitachi Co., Tokyo, Japan) with negative staining using uranyl acetate. 
 
2.5. In-vitro gene expression and intracellular distribution experiments  
The human vascular endothelial cell line EAhy926 was purchased from American Type Culture 
Collection (Manassas, VA, USA) and the cells were maintained in Dulbecco’s modified Eagle medium 
supplemented with 10% fetal bovine serum, 100 IU/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine, 
and 100 μM non-essential amino acids at 37°C in 5% CO2. Following a pre-incubation period of 24 hr, the culture 
medium was replaced with Opti-MEM I containing different complexes (10 μg pDNA). The EAhy926 cells were 
then exposed to US (frequency, 2.0 MHz; duty, 50%; burst rate, 10 Hz; intensity 4.0 W/cm2) for 20 seconds using a 
6-mm diameter probe, which was placed in the well 10 min after the addition of the different complexes. The US 
was generated using a Sonopore-4000 sonicator (Nepa Gene, Co., Ltd., Chiba, Japan). The incubation medium was 
then replaced with the culture medium and the resulting mixture was incubated for an additional 24 hr. Following 
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the incubation period, the cells were suspended in lysis buffer (0.05% Triton X-100, 2 mM EDTA, and 0.1 M Tris; 
pH 7.8), and the lysate was mixed with luciferase assay buffer (Picagene, Toyo Ink Co., Ltd., Tokyo, Japan). The 
luciferase activity was then measured using a luminometer (Lumat LB 9507, EG&G Berthold, Bad Wildbad, 
Germany) and normalized with respect to the protein content of the cells using a Protein Quantification Kit 
(Dojindo Molecular Technologies, Inc., Tokyo, Japan). 
The intracellular distribution of the pDNA was determined using fluorescein-labeled pDNA and 
LysoTracker Red DND-99 (Invitrogen, Carlsbad, CA, USA). Briefly, the cells were transfected with the 
pDNA/PS/BL or Lipofectamine 2000 (Invitrogen) using fluorescein-labeled pDNA. The cells were subsequently 
treated with LysoTracker Red DND-99 6 hr after the transfection process, and then fixed using a 10% formalin 
solution before being stained with DAPI and observed under a confocal microscope (Nikon A1RMP, Nikon, Tokyo, 
Japan). 
 
2.6. WST-1 assay 
The cytotoxicities of the bubble lipopolyplexes towards the EAhy926 cells were determined using a 
WST-1 Cell Proliferation Reagent (Roche Diagnostics Corporation, Indianapolis, IN, USA). Following a 
pre-incubation period of 24 hr, the different bubble lipopolyplexes containing 10 µg of pDNA in the culture 
medium were added to the EAhy926 cells and incubated for 10 min before being exposed to US in the same 
manner as the cells described above. Following their exposure to the US, the cells were incubated for 24 hr with the 
different bubble lipopolyplexes. The medium was replaced with the culture medium and the WST-1 Cell 
Proliferation Reagent was added to each well. The cells were then incubated for 2 hr at 37°C and the absorbance in 
each well was measured at a wavelength of 450 nm with a reference wavelength of 630 nm using an EON 
Microplate Spectrophotometer (BioTek, Winooski, VT, USA). The results are shown as the percentage of untreated 
cells (control). 
 
2.7. Erythrocyte aggregation experiment 
Erythrocytes from mice were washed three times with PBS at 4°C by centrifugation at 5000 ×g for 5 min 
and 2% (v/v) stock suspensions of the resulting erythrocytes were then prepared in PBS. A 40-μL of the erythrocyte 
suspension were mixed with 40 μL of the cationic polyplexes or the anionic bubble lipopolyplexes solution 
containing 5 μg of pDNA, and the resulting mixture was incubated for 15 min at ambient temperature. 
Lipofectamine 2000 and PEI were used for the positive control. A 30-μL of pDNA solution containing 5 μg of 
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pDNA was mixed with 10 μL of Lipofectamine 2000 or PEI solution (0.5 mg/mL) and the resultant solution was 
mixed with the erythrocyte suspension as described above. A 10-µL sample of the mixture was then collected and 
placed on a glass plate to allow for the aggregation to be observed by microscopy.  
 
2.8. Animals 
All of the animal experiments were performed in accordance with the Principles of Laboratory Animal 
Care, as adopted and promulgated by the US National Institutes of Health, and the guidelines for animal 
experiments of Kyoto University. Female ICR mice (5–6 weeks old) were purchased from Japan SLC (Shizuoka, 
Japan). Following their shipping, the mice were acclimatized to the environment for at least 1 day before each 
experiment. 
 
2.9. In-vivo gene expression experiment 
The mice were intravenously injected with 400 μL of the bubble lipopolyplexes via the tail vein using a 
26-gauge syringe needle at a dose of 50 μg of pDNA. Immediately after the injection of the bubble lipopolyplexes, 
US (frequency, 1.0 MHz; duty, 50%; burst rate, 10 Hz; intensity, 0.5 W/cm2; time, 1 min) was applied 
transdermally to the abdominal area using a Sonopore-4000 sonicator with a probe (diameter: 20 mm). Six hours 
after the injection, the mice were sacrificed and their organs, including their liver, kidney, and spleen, were 
collected for each experiment. The collected organs were then washed twice with cold saline and homogenized in 
the lysis buffer. The lysis buffer was added in a weight ratio of 5 mL/g for the liver or 4 mL/g for the other organs. 
The homogenates were centrifuged at 15,000 × g for 10 min at 4°C. The luciferase activities of the resulting 
supernatants were then determined. 
 
2.10. Separation of hepatic parenchymal cells and non-parenchymal cells 
The separation of mouse hepatic parenchymal cells and non-parenchymal cells was performed as 
previously described in the literature [33]. The parenchymal and non-parenchymal liver cells were resuspended 
separately in the lysis buffer and their luciferase activity was determined. Furthermore, Kupffer cells and liver 
endothelial cells were separated from the non-parenchymal cells with an immunomagnetic cell isolation system 
(Robosep, Veritas Corp., Tokyo, Japan) using FITC labeled anti-CD14 and anti-CD31 antibodies (Abcam, Tokyo, 
Japan) with a RoboSep Mouse FITC Selection Kit (Veritas Corp., Tokyo, Japan). The total RNA was extracted 
from the cells using a GenElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich, St. Louis, MO, USA). 
9 
 
Reverse transcription of the mRNA to cDNA was carried out using a PrimeScript RT reagent Kit (Takara Bio Inc., 
Shiga, Japan). Luciferase and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA expression were 
determined with a Lightcycler 2.0 real-time PCR system (Roche Diagnostics, Indianapolis, IN, USA), using an 
SYBR Premix Ex Taq (Takara Bio Inc.). Primers for the luciferase and GAPDH were constructed according to the 
following procedure. Primer for luciferase, 5’-TTCTTCGCCAAAAGCACTC-3’ (forward) and 
5’-CCCTCGGGTGTAATCAGAAT-3’ (reverse); primer for GAPDH, 5’-TCTCCTGCGACTTCAACA-3’ 
(forward) and 5’-GCTGTAGCCGTATTCATTGT-3’ (reverse) (Invitrogen). 
 
2.11. Hepatic toxicity of the pDNA/PS/BL with or without US exposure 
The mice were transfected with pDNA/PS/BL containing 25 μg of pDNA and subsequently exposed to 
US, as described above. Blood samples were then collected from the vena cava under pentobarbital anesthesia at 
predetermined time points. A hydrodynamic transfection experiment was also performed as a positive control for 
liver toxicity involving the administration of pDNA dissolved in 2.5 mL of saline into the tail vein of mice within 5 
seconds [10]. Cationic liposomes composed of DOTAP and cholesterol (Chol) were prepared as previously 
described [34]. DOTAP/Chol liposomes were mixed with pDNA at charge ratios (-:+) of 1.0:2.3. 
pDNA-DOTAP/Chol complexes (DOTAP/Chol lipoplexes) were also constructed as a positive control for cytokine 
production. The serum aspartate transaminase (AST) and alanine transaminase (ALT) activities were then 
determined using a Transaminase CII-Test Wako kit (Wako Pure Chemical Industries, Ltd.) according to the 
manufacturer’s instructions. The levels of TNF-α and IL-6 in the serum were then evaluated using a BD OptEIA 
ELISA Set (BD, Franklin Lakes, NJ, USA). 
 
2.12. Statistical analysis 
Statistically significant differences between the two groups were identified by the Mann-Whitney U test. 
Multiple comparisons were made between the different groups using Scheffe’s test with ANOVA, whereas multiple 




3.1. Physicochemical properties of the anionic bubble lipopolyplexes 
The particles of the cationic polyplexes were approximately 130 to 150 nm in size, with zeta-potentials in 
the range of 25 to 55 mV (Table 1). Addition of anionic liposomes to the cationic polyplexes extensively decreased 
zeta-potentials with partial effect on the particle sizes. The trapping of the perfluoropropane gas led to an increase 
in the particle size of the anionic lipopolyplexes, with the particles becoming 450 to 600 nm in size. The trapping of 
the gas, however, had little effect on the zeta-potential. Following the trapping of the gas, the lipopolyplex solutions 
became cloudy in appearance, as shown Fig. 1a. TEM images were then taken to allow for a detailed view of the 
structure of the pDNA/PS, pDNA/PS/AL, and pDNA/PS/BL (Fig. 1b). Those TEM images revealed that AL coated 
on the surface of pDNA/PS and the pDNA/PS/BL existed as a cluster of bubble liposomes. The formation of the 
complex through electrostatic interactions with or without US exposure was clarified by gel electrophoresis (Fig. 
2).  
 
3.2. In-vitro gene expression experiments 
 The cationic polyplexes, anionic lipopolyplexes, and anionic bubble lipopolyplexes were added to the 
EAhy926 cells to determine their transgene efficiencies (Fig. 3). The results revealed that the transgene efficiencies 
of the cationic polyplexes and anionic lipopolyplexes were not affected by exposure to the US. In contrast, US 
exposure significantly increased the level of gene expression in the anionic bubble lipopolyplexes, including the 
pDNA/PS/BL, pDNA/PLL/BL, pDNA/PLA/BL, and pDNA/DPLL/BL systems (P < 0.01), where the levels of 
gene expression were significantly higher than those in the cationic polyplexes and anionic lipopolyplexes (P < 
0.01 or P < 0.05). Of the anionic bubble lipopolyplexes tested in the current study, the pDNA/PS/BL with US 
exposure showed the highest level of gene expression. 
 
3.3. Intracellular distribution experiments 
 The intracellular distribution of the anionic bubble lipopolyplexes composed of pDNA/PS/BL with or 
without US exposure was determined by confocal microscopy (Fig. 4). The nucleus, pDNA, and lysosomes were 
indicated as blue, green, and red fluorescein, respectively. As shown in Fig. 4a, the pDNA was mainly localized 
with the lysosomes as yellow dots following transfection using Lipofectamine 2000. The co-localization of the 
pDNA and lysosomes (yellow dots) was also observed in the cells transfected with pDNA/PS/BL without US 
exposure (Fig. 4b). In contrast, the pDNA and lysosomes were found to be separate from each other in the cells 
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transfected by pDNA/PS/BL with US exposure (Fig. 4c). 
 
3.4. Cytotoxicity and erythrocyte aggregation 
 The cytotoxicities of the anionic bubble lipopolyplexes towards the EAhy926 cells were determined 
using a WST-1 assay (Fig. 5). Although US exposure did not affect the cell viability, significant levels of 
cytotoxicity (P < 0.05 or P < 0.01) were observed in the cells treated with the anionic bubble lipopolyplexes, except 
for pDNA/PS/BL.  
 The cationic lipoplexes and polyplexes, and anionic bubble lipopolyplexes were mixed with erythrocytes 
and the aggregation levels were determined (Fig. 6). The cationic lipoplexes that had been prepared with 
Lipofectamine 2000 caused aggregation of the erythrocytes and hemolysis (Fig. 6b). The cationic polyplexes such 
as pDNA/PEI, pDNA/PS, pDNA/PLL, pDNA/PLA, and pDNA/DPLL showed extensive aggregation (Fig. 6c, d, f, 
h, and j, respectively). In contrast, no significant levels of aggregation or hemolysis were determined in the anionic 
bubble lipopolyplexes (Fig. 6e, g, i, and k). 
 
3.5. In-vivo gene expression experiments 
Various anionic bubble lipopolyplexes were intravenously administrated and the abdominal areas of the 
mice were then exposed to US. The levels of gene expression in the liver, kidney, and spleen were then determined 
(Fig. 7a, b, and c, respectively). The anionic bubble lipopolyplexes without US exposure showed extremely low 
levels of gene expression, whereas US exposure in these cases led to a significant increase (P < 0.05 or P < 0.01) in 
gene expression in the liver, kidney, and spleen. 
 
3.6. Effect of anionic lipids constructing anionic liposomes in the anionic bubble lipopolyplexes (pDNA/PS/BL) 
The effects of the anionic lipids of the anionic liposomes in the anionic bubble lipopolyplexes on the 
in-vitro transfection efficiency, in-vivo transfection efficiency, and cytotoxicity were determined (Fig. 8a, b, and c, 
respectively). The DSPA containing the anionic bubble lipopolyplexes (pDNA/PS/BL) with US exposure showed 
the lowest transfection efficiency of all of the systems tested, both in-vitro and in-vivo (Fig. 8a and b). The DSPA 
and DSPS containing the anionic bubble lipopolyplexes (pDNA/PS/BL) with US exposure showed a slight 
reduction in cell viability (Fig. 8c). In contrast, the DSPG containing the anionic bubble lipopolyplexes 





3.7. Intrahepatic gene expression resulting from the anionic bubble lipopolyplex (pDNA/PS/BL) 
Liver parenchymal cells and non-parenchymal cells were separated by collagenase perfusion and their 
levels of luciferase expression were determined. The anionic bubble lipopolyplex (pDNA/PS/BL) with US 
exposure showed significantly higher levels of gene expression in liver non-parenchymal cells than parenchymal 
cells (P < 0.05) (Fig. 9a). Determination of the levels of luciferase mRNA revealed that the anionic bubble 
lipopolyplex with US exposure showed significantly higher levels of expression in liver non-parenchymal cells 
(Kupffer cells and liver endothelial cells) than parenchymal cells (P < 0.05). Furthermore, the levels of mRNA 
expression in the Kupffer cells and liver endothelial cells were almost identical in the liver non-parenchymal cells 
(Fig. 9b). 
 
3.8. In-vivo toxicity by the anionic bubble lipopolyplex (pDNA/PS/BL) 
 The serum AST and ALT activities of the anionic bubble lipopolyplex (pDNA/PS/BL) were determined 
with or without US exposure (Fig. 10a and b, respectively). Very little hepatic toxicity was observed for the anionic 
bubble lipopolyplex (pDNA/PS/BL) with or without US exposure. The use of the hydrodynamic method as a 
positive control led to significant increases in the serum AST and ALT activities. The effects of the anionic bubble 
lipopolyplex (pDNA/PS/BL) with or without US exposure on the level of serum inflammatory cytokines such as 
TNF-α (Fig. 11a) and IL-6 (Fig. 11b) were also evaluated. The results revealed that the anionic bubble lipopolyplex 
(pDNA/PS/BL) with or without US exposure had no discernible impact on cytokine production. The use of 




For clinical applications, it is important that non-viral carrier materials are composed of biocompatible 
and/or biodegradable constituents. To date, various biodegradable cationic polymers have been developed, 
including PS, PLL, and octa-arginine. In all of these cases, however, the transfection efficiencies were poor because 
materials did not exhibit any endosomal escape properties following endocytosis [35-37]. Endosomolytic gene 
delivery carriers such as PEI and cationic liposomes have recently been developed for effective transfection [38, 
39]. Unfortunately, however, these polyplexes and lipoplexes possess a cationic charge and can interact with 
biogenic substances to become cytotoxic at high concentrations [30]. One promising approach for overcoming 
these safety issues involves the construction of neutral or anionic charged carriers from ternary complexes, and 
ternary complexes of this type have been reported to possess an anionic surface charge and show lower levels of 
toxicity than cationic gene delivery carriers [40, 41]. In the current study, we have developed for the first time 
anionic bubble lipopolyplexes that are ternary complexes of pDNA, cationic polymers, and anionic bubble 
liposomes with biocompatible compounds to be used for efficient and safe transfection processes.  
The sonoporation method has been used in the current study because this method has been reported to 
deliver genes directly into the cytosol [14-17, 25, 27]. To prepare an anionic bubble formulation, the pDNA was 
initially condensed by the biodegradable cationic polymers. The anionic lipopolyplexes were subsequently prepared 
by coating the resulting cationic polyplexes with AL. In the TEM images, AL was observed on the surface of the 
pDNA/PS/AL and the zeta-potentials of those cationic polyplexes were turned from positive to negative by 
additions of AL (Fig. 1b and Table 1). Those results support that the AL is coating those cationic polyplexes. The 
bubble lipopolyplexes were then formed through the encapsulation of perfluoropropane gas. The particles of the 
anionic lipopolyplexes, including pDNA/PS/AL, pDNA/PLL/AL, pDNA/PLA/AL, and pDNA/DPLL/AL, were 
approximately 160 to 200 nm in size with zeta-potentials in the range of -20 to -40 mV (Table 1). The encapsulation 
of the perfluoropropane gas led to an increase the particle size of the lipopolyplexes, which became approximately 
450 to 600 nm in size, although the encapsulation process had very little impact on the zeta-potential values (Table 
1). Given that the use of the saturated lipids of liposomes is essential to the encapsulation of perfluoropropane gas 
in bubble lipoplexes [27, 42], we prepared AL using a range of saturated lipids, such as DSPG, DSPA, DSPS, 
PEG-DSPE, and DSPC. The particle sizes of the anionic bubble lipopolyplexes were found to be almost identical to 
those of the mannosylated cationic bubble lipoplexes reported in our previous paper [27]. Electron microscopy was 
then used to confirm the structure of the anionic bubble lipopolyplex (pDNA/PS/BL). To date, there have been very 
few reports in the literature concerning the use of bubble lipoplexes. As shown in Fig. 1b, the TEM image of the 
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pDNA/PS/BL system revealed that this material existed as a cluster of anionic bubble liposomes. The particle sizes 
of these anionic bubble lipopolyplexes were also very similar to those measured using a Zetasizer Nano ZS (Table 
1). The anionic liposomes on the surface of the pDNA/PS/AL were crowded as a consequence of electrostatic 
interactions with the cationic polyplex (pDNA/PS), and steric hindrance from the anionic liposomes could 
potentially complicate any expansion. Further study is needed, however, to clarify the detailed structure of these 
anionic bubble lipopolyplexes.  
Some polyanions such as heparin sulfate have been reported to dissociate polyplexes, with the pDNA 
being released from the polyplexes as a consequence [43]. To examine complex formation in the bubble 
lipopolyplexes, the release of pDNA from the anionic bubble lipopolyplexes was evaluated by gel electrophoresis 
(Fig. 2). The migration of pDNA was not detected in the polyplexes, lipopolyplexes, bubble lipopolyplexes, or 
bubble lipopolyplexes with US exposure. These results suggested that the pDNA is retained in the anionic bubble 
lipopolyplexes regardless of the addition of anionic liposomes, the encapsulation of perfluoropropane gas or the US 
exposure procedure.  
Polyplexes constructed from biodegradable polymers such as PS and PLL have been reported to show 
low levels of gene expression [35, 36]. In general, anionic nanoparticles are not taken up by cells that possess an 
anionic charge because of electric repulsion. In contrast, the use of microbubbles in conjunction with US exposure 
can deliver pDNA directly into the cytosol by creating transient pores on the cellular membrane, and this technique 
shows high levels of gene expression [15, 17]. The anionic bubble lipopolyplexes with US exposure were therefore 
expected to give high gene expression potency. The transfection efficacy of the anionic bubble lipopolyplexes with 
US exposure was much higher than those without US exposure in EAhy926 cells (Fig. 3) and in mice (Fig. 7). In 
case of the absence of US exposure, the anionic bubble lipopolyplexes showed lower gene expression than the 
anionic lipopolyplexes (Fig. 3). It might be due to sizes of the anionic bubble lipopolyplexes which were 
approximately four times bigger than the anionic lipopolyplexes (Table 1). To assess the intracellular localization of 
the anionic bubble lipopolyplexes, we observed the intracellular distribution of the anionic bubble lipopolyplex 
(pDNA/PS/BL) in EAhy926 cells with or without US exposure (Fig. 4). When the cells were transfected with 
Lipofectamine 2000, 47.4% of the pDNA was reported to have remained in the lysosomes [44]. We also observed 
that the pDNA was highly localized in the lysosomes following transfection with Lipofectamine 2000 (Fig. 4a). 
The co-localization of pDNA and lysosomes was also observed in cells transfected with the anionic bubble 
lipopolyplex (pDNA/PS/BL) without US exposure (Fig. 4b). In contrast, barely any pDNA was observed in the 
lysosomes in cells transfected with the anionic bubble lipopolyplex (pDNA/PS/BL) with US exposure (Fig. 4c). 
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These intracellular distribution characteristics supported the high gene expression of the anionic bubble 
lipopolyplex (pDNA/PS/BL) with US exposure.  
It has been reported that the coating of cationic lipoplexes or polyplexes with anionic polymers markedly 
reduces the toxicity properties of cationic lipoplexes or polyplexes such as their cytotoxicity towards cultured cells, 
hepatic toxicity, and proinflammatory cytokine production properties [40, 45-47]. With this in mind, we evaluated 
the safety profile of the current anionic bubble lipopolyplexes, including their aggregation with erythrocytes, 
cytotoxicity, liver toxicity, and cytokine production. As shown in Fig. 6e, g, i, and k, the anionic bubble 
lipopolyplexes exhibited low levels of interaction with erythrocytes even when the transfection reagent 
(Lipofectamine 2000, Fig. 6b) and cationic polyplexes such as pDNA/PEI, pDNA/PS, pDNA/PLL, pDNA/PLA, 
and pDNA/DPLL (Fig. 6c, d, f, h, and j) showed high levels of aggregation, with the transfection reagent in 
particular also showing hemolysis (Fig. 6b). In contrast, the use of anionic bubble lipopolyplexes with US exposure 
led to a slight reduction in cell viability. pDNA/PS/BL in particular showing the lowest cytotoxicity of the four 
types of anionic bubble lipopolyplexes tested in the current study (Fig. 5). Furthermore, the lowest cytotoxicity was 
observed in the anionic bubble lipopolyplex (pDNA/PS/BL) containing DSPG (Fig. 8c). In addition, the anionic 
bubble lipopolyplex (pDNA/PS/BL) containing DSPG showed the highest gene expression in in-vitro and in-vivo 
(Fig. 8a and b). On the basis of these results, we decided to use pDNA/PS/BL containing DSPG in the subsequent 
experiments as an optimized formulation for efficient and safe gene transfer. We then proceeded to evaluate the 
hepatic toxicity and production of proinflammatory cytokines by the anionic bubble lipopolyplex (pDNA/PS/BL) 
with US exposure (Figs. 10 and 11). The anionic bubble lipopolyplex had no discernible impact on the serum AST 
and ALT activities, and did not give rise to an increase in the serum TNF-α and IL-6 levels. When pDNA is taken 
up by cells through the endocytosis, TLR9 on the endosomal membranes recognizes the CpG motif in pDNA and 
produces proinflammatory cytokine [48]. The anionic bubble lipopolyplex (pDNA/PS/BL) is considered to have a 
core-shell structure capable of shielding pDNA in the core (Figs. 1b and 2). Uchida and Kataoka et al. reported the 
development of a PEGylated polyplex with optimized PEG shielding that minimized the inflammatory response 
[49]. These results therefore lead us to believe that the core-shell structure of the anionic bubble lipopolyplex 
(pDNA/PS/BL) would result in the low TLR9 recognition and low cytokine production.  
As far as the gene expression in the liver is concerned, the anionic bubble lipopolyplex (pDNA/PS/BL) 
with US exposure showed significantly higher levels of gene expression in liver non-parenchymal cells (i.e., 
Kupffer cells and liver endothelial cells) than in parenchymal cells (P < 0.05) (Fig. 9). These results can be 
explained in terms of the size of the anionic bubble lipopolyplex (approximately 500 nm) being much larger than 
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that of sinusoidal fenestrae (< 150 nm) [50]. The anionic bubble lipopolyplexes could therefore not pass efficiently 
through the sinusoidal fenestrae. As a consequence, the pDNA would be transferred to the liver non-parenchymal 
cells rather than the liver parenchymal cells. 
It would be necessary to prepare the anionic bubble lipopolyplexes from biocompatible materials for their 
clinical application. In the current study, the anionic bubble lipopolyplex (pDNA/PS/BL) was constructed from 
pDNA, PS, and bubble liposomes (AL and perfluoropropane gas). The PS has been used clinically to neutralize the 
anticoagulant effect of heparin [51]. The lipids of AL, including DSPG, DSPC, and PEG-DSPE, have been used 
clinically as additives for an number of different drugs, including Ambisome, DaunoXome, and Doxil, respectively 




In the current study, we have successfully constructed an anionic bubble lipopolyplex as a novel gene 
delivery carrier. This material was prepared as a ternary complex of pDNA, cationic polymer, and an anionic 
bubble liposome using biocompatible materials for efficient and safe gene transfection with US exposure. The 
anionic bubble lipopolyplex showed high levels of gene expression in-vitro and in-vivo only after US exposure. 
Furthermore, this material did not give rise to any liver toxicity or proinflammatory cytokine production. Anionic 
bubble lipopolyplex of this type could be used as novel formulation tools for effective and safe transfection 
processes, and we believe that the information provided in this report could provide a platform for the development 
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Table 1. Particle size and zeta-potential data for the bubble lipopolyplexes 
136.33 ± 3.18 25.87 ± 0.15
202.3 ± 3.8 -39.8 ± 0.2
563.0 ± 40.7 -39.2 ± 1.8
137.3 ± 2.5 55.0 ± 0.2
161.0 ± 1.0 -32.0 ± 0.1
586.7 ± 27.6 -44.4 ± 0.7
149.3 ± 2.8 52.4 ± 1.3
179.6 ± 3.6 -32.0 ± 0.2
457.2 ± 140.0 -28.5 ± 0.6
145.7 ± 5.3 51.0 ± 2.2
169.5 ± 1.2 -21.3 ± 0.5




















Fig. 1. Photographs and TEM image of bubble lipopolyplexes 
(a) Bubble lipopolyplexes (right) were prepared by sonication of the lipopolyplexes (left) with supercharged 
perfluoropropane gas. (b) The pDNA/PS, pDNA/PS/AL, and pDNA/PS/BL were observed by TEM with negative 
staining using uranyl acetate. 
 
Fig. 2. Agarose gel electrophoresis of various complexes. 
Each complex was loaded onto agarose gel for electrophoresis. Retardation of pDNA was visualized using a 
GelRed Nucleic Acid Gel Stain. 
 
Fig. 3. In-vitro transgene efficiency of various complexes. 
EAhy926 cells were transfected with different complexes with or without US exposure. The cells were then 
incubated for 24 hr after transfection and the level of luciferase gene expression was determined. Each bar 
represents the mean + S.E.. **: P<0.01 vs all other groups; ##: P<0.01; #: P<0.05. 
 
Fig. 4. Intracellular distribution of the pDNA. 
Cells were transfected with fluorescein-labeled pDNA using Lipofectamine 2000 (a), pDNA/PS/BL (b), and 
pDNA/PS/BL with US (c). Six hours after transfection, the nuclei and lysosomes were stained by DAPI and 
LysoTracker Red DND-99, respectively. The merged images of the nuclei (blue), pDNA (green), and lysosomes 
(red) using confocal microscopy are shown. 
 
Fig. 5. Cytotoxicity tests of the different complexes towards EAhy926 cells. 
The viabilities of the cells treated with different complexes were measured by WST-1 assay. The different 
complexes were added to the cells and the cells subsequently exposed to US. The cells were incubated with 
complexes for 24 hr and the cell viability was measured. Data represents the percentage to untreated cells. Each bar 
represents the mean + S.E. **: P<0.01; *: P<0.05 vs control. 
 
Fig. 6. Aggregation of complexes with erythrocytes. 
PBS (a), pDNA/Lipofectamine 2000 (b), pDNA/PEI (c), pDNA/PS (d), pDNA/PS/BL (e), pDNA/PLL (f), 
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pDNA/PLL/BL (g), pDNA/PLA (h), pDNA/PLA/BL (i), pDNA/DPLL (j), and pDNA/DPLL/BL (k) were added to 
the erythrocytes, and the aggregation was observed by phase microscopy. 
 
Fig. 7. In-vivo transgene efficiency of bubble lipopolyplexes 
ICR female mice were intravenously injected with bubble lipopolyplexes via the tail vein at a dose of 50 μg of 
pDNA. US was applied transdermally to the abdominal area immediately after the injection of the bubble 
lipopolyplexes. Six hours after administration, the mice were sacrificed and the luciferase activities in the liver (a), 
kidney (b), and spleen (c) were determined. Each bar represents the mean + S.E. **: P<0.01; *: P<0.05 vs each US 
(-) group. 
 
Fig. 8. Effect of anionic lipids on the luciferase expression and cytotoxicity of pDNA/PS/BL 
(a) EAhy926 cells were transfected with the different complexes with or without US exposure. Cells were 
incubated for 24 hr after transfection and the luciferase gene expression was determined. Each bar represents the 
mean + S.E. **: P<0.01. (b) ICR female mice were intravenously injected with bubble lipopolyplexes via the tail 
vein at a dose of 50 μg of pDNA. US was then applied transdermally to the abdominal area immediately after the 
injection of the bubble lipopolyplexes. Six hours after administration, the mice were sacrificed and the luciferase 
activities in their liver, kidney, and spleen were determined. Each bar represents the mean + S.E. *: P<0.05. (c) 
Viability of EAhy926 cells treated with the different complexes was measured by WST-1 assay. Different 
complexes were added to cells and the cells were subsequently exposed to US. Cells were incubated with 
complexes for 24 hr and the cell viability was measured. Data represent the percentage to untreated cells. Each bar 
represents the mean + S.E. *: P<0.05 vs control. 
 
Fig. 9. Hepatic cellular localization of luciferase expression by pDNA/PS/BL 
pDNA/PS/BL was intravenously administrated into mice. US was then applied transdermally to the abdominal area 
immediately after the injection of the bubble lipopolyplexes. Six hours after administration, liver parenchymal cells 
and non-parenchymal cells were separated by the collagenase perfusion. Luciferase activity in the cells was 
determined (a). Kupffer cells and endothelial cells were separated by the immunomagnetic cell isolation system 
from non-parenchymal cells and the luciferase mRNA expression was determined (b). Each bar represents the mean 




Fig. 10. Hepatic toxicity of pDNA/PS/BL 
pDNA/PS/BL was intravenously administrated into mice. US was then applied transdermally to the abdominal area 
immediately after injection of bubble lipopolyplexes. Serum was collected at 6, 12, and 24 hr after administration. 
The serum AST (a) and ALT (b) activities were determined using a Transaminase CII-Test Wako kit. Each bar 
represents the mean ± S.E. **: P<0.01 (Hydrodynamic methods); #: P<0.05 (bubble lipopolyplexes US (-)); ††: 
P<0.01 (bubble lipopolyplexes US (+)) vs group of non-treated. 
 
Fig. 11. Proinflammatory cytokine induction by pDNA/PS/BL 
pDNA/PS/BL was intravenously administrated into mice. US was then applied transdermally to the abdominal area 
immediately after injection of bubble lipopolyplexes. Serum was collected at 6, 12, and 24 hr after administration. 
The serum TNF-α (a) and IL-6 (b) levels were determined by ELISA. Each bar represents the mean ± S.E. **: 
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